{'fraction_non_alphanumeric': 0.019595448798988623, 'fraction_numerical': 0.019595448798988623, 'mean_word_length': 5.111969111969112, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Safety and Efficacy of Dinogest in Long Term Treatment of Endometriosis

Introduction: Endometriosis is a chronic disease characterized by the prolifera tion of endometrial tissue outside the uterine cavity, and it occurs in 6% to 10% of women of reproductive age and in 50% of infertile women. Current research aimed to study the safety and efficacy of dinogest 2mg daily in patients of endometriosis for a period of 12 months. Material and methods: This study was a retrospective non placebo randomized trial done in the department of obstetrics and gynaecology, RMCH. Patient data was collected in a span of 1year i.e; February 2018 to January 2019 and dinogest was given for 12 months thereafter. Total 100 women post surgery (cystectomy) with endometriosis were taken who had been treated with 2mg of dinogest once a day for 12 months. We evaluated changes in endometriosis associated pain, endometrioma size, recurrence rate and adverse events. Result: Pain was significantly reduced at 12 months after dinogest medication. The size of endometrioma was significantly decreased at the 12th month. Only 1 case of sonographic recurrence was seen. The most common adverse drug reaction was uterine bleeding (1%) with minor side effects which became gradually tolerable. Conclusion: Administration of dinogest for a one year period seems to be highly effective in preventing recurrence after surgery, there was marked reduction in endometriosis associated pain and decreasing the size of recurrent endometrioma. So, it is very safe and tolerable drug for treatment of endometriosis